Zevra Therapeutics Reports Strong Q2 2025 Results, Seeks European Approval for MIPLYFFA
Key Insights
Zevra Therapeutics achieved Q2 2025 net revenue of $25.9 million, driven primarily by $21.8 million in product revenue, marking significant growth from $4.4 million in Q2 2024.
The company completed the sale of its Pediatric Rare Disease Priority Review Voucher for $150 million, providing non-dilutive capital to support commercial launches and development programs.
Zevra submitted a Marketing Authorisation Application to the European Medicines Agency (search) for arimoclomol (MIPLYFFA) to treat Niemann-Pick Disease Type C (search), seeking to expand access beyond the U.S. market.
Zevra Therapeutics reported robust financial results for the second quarter of 2025, with net revenue reaching $25.9 million driven by strong product sales and strategic asset monetization. The commercial-stage rare disease company's performance was anchored by $21.8 million in product net revenue, representing substantial growth from the $4.4 million total net revenue reported in Q2 2024.
The quarter's standout achievement was the completion of Zevra's Pediatric Rare Disease Priority Review Voucher (PRV) sale for $150.0 million, which significantly strengthened the company's balance sheet and provided non-dilutive capital for ongoing commercial launches and development programs. This strategic transaction positioned Zevra with enhanced financial flexibility to execute its growth initiatives.
MIPLYFFA Commercial Progress and European Expansion
MIPLYFFA, Zevra's approved therapy for Niemann-Pick Disease Type C (search) (NPC), demonstrated continued commercial momentum with 7 prescription enrollment forms processed during Q2 2025, bringing the total since product launch to 129. Market access for MIPLYFFA has reached 52% of covered lives, aligning with the company's expectations for this stage of the launch.
"Following approval late last year, we are focused on executing the U.S. launch of MIPLYFFA, and we believe the remarkable performance in the second quarter sets a strong foundation for continued momentum," said Neil F. McFarlane, Zevra's President and Chief Executive Officer. "As the only treatment that has been shown to halt disease progression by addressing its underlying pathology, we are invigorated by the meaningful impact MIPLYFFA is bringing to people diagnosed with Niemann-Pick disease type C (search)."
A significant milestone for the quarter was Zevra's submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (search) (EMA) for the evaluation of arimoclomol for NPC treatment. This regulatory filing represents the company's strategic effort to expand MIPLYFFA's reach to European patients suffering from this debilitating rare disease. Arimoclomol has received Orphan Medicinal Product designation from the EMA for NPC treatment.
MIPLYFFA's clinical profile is supported by extensive data from more than 270 NPC patients worldwide through Phase 2/3 clinical trials, Open-Label Extension studies, Expanded Access Programs, and pediatric sub-studies. In the pivotal Phase 3 trial, MIPLYFFA demonstrated the ability to halt disease progression compared to placebo over one year when measured by the NPC Clinical Severity Scale, the only validated disease progression measurement tool for this condition.
Pipeline Development and Financial Position
Zevra's pipeline advancement continued with the enrollment of 7 patients in the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome (search) during Q2 2025, bringing total enrollment to 39 patients. Celiprolol has received both Orphan Drug and Breakthrough Therapy designations from the U.S. FDA (search) and is being evaluated under a Special Protocol Assessment agreement.
The company's financial position was further strengthened by a robust cash position of $217.7 million in cash, cash equivalents, and securities as of June 30, 2025. Based on current operating forecasts, Zevra believes it has sufficient resources and financial flexibility to execute strategic priorities independent from capital markets.
Product Portfolio Performance
Beyond MIPLYFFA, Zevra's OLPRUVA (search) (sodium phenylbutyrate) for urea cycle disorders (search) processed 1 prescription enrollment form during Q2 2025, bringing the total since product launch to 29. Market access for OLPRUVA has increased to 79% of covered lives.
The quarter's financial results included $21.5 million of MIPLYFFA net revenue, $0.3 million of OLPRUVA (search) net revenue, $2.6 million in net reimbursements from the French Expanded Access Program for arimoclomol, and $1.2 million in royalties under the AZSTARYS license agreement.
Operating expenses totaled $24.2 million for Q2 2025, including $2.5 million in non-cash stock compensation expense. Research and development expenses decreased to $3.4 million, down $7.1 million compared to Q2 2024, primarily due to reduced third-party costs following completion of the KP1077 Phase 2 trial.
The company reported net income of $74.7 million, or $1.24 per basic share, for Q2 2025, compared to a net loss of $19.9 million in the prior year period. Excluding the one-time PRV sale proceeds and certain non-cash charges, adjusted net loss was $3.2 million for the quarter.